Handel nachbörslich: 20.91

Exelixis Inc (EXEL)

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

Exelixis Inc (EXEL)

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by BNP Paribas Financial Markets - MarketBeat

July 19th Options Now Available For Exelixis (EXEL) - Nasdaq

Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Victory Capital Management Inc. - Defense World

BNP Paribas Financial Markets Has $10.80 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

Exelixis, Inc. (NASDAQ:EXEL) Stock Holdings Lifted by M&T Bank Corp - Defense World

Coherus BioSciences (NASDAQ:CHRS) versus Exelixis (NASDAQ:EXEL) Critical Contrast - Defense World

Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805 - Yahoo New Zealand News

Exelixis (NASDAQ:EXEL) Research Coverage Started at Stephens - Defense World

Exelixis director Jack Wyszomierski sells shares worth over $230k - Investing.com Australia

Exelixis director Jack Wyszomierski sells shares worth over $230k - Investing.com

Exelixis director Jack Wyszomierski sells shares worth over $230k - Investing.com UK

Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC - Yahoo Movies UK

Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA - Yahoo News UK

Exelixis director Jack Wyszomierski sells shares worth over $230k - Investing.com South Africa

Exelixis (NASDAQ:EXEL) Receives New Coverage from Analysts at Stephens - MarketBeat

Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Lifestyle UK

Oversold Conditions For Exelixis (EXEL) - Nasdaq

Exelixis reports new USP1 inhibitors - BioWorld Online

Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Charles Schwab Investment Management Inc. - Defense World

Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth - Yahoo Movies Canada

Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?

Swiss National Bank Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Exelixis sues Cipla over Cabometyx generics (NASDAQ:EXEL) - Seeking Alpha

Exelixis (EXEL) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Movies Canada

Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Swiss National Bank - Defense World

Exelixis Files Patent Complaint Against Cipla's Cancer Treatment - MarketWatch

MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By ... - Markets Insider

MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'

Exelixis price target raised to $29 vs. $25 at Oppenheimer - MSN

Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by LSV Asset Management - MarketBeat

Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo News UK

New York Life Investment Management LLC Decreases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

Top Ranked Momentum Stocks to Buy for June 27th - Yahoo News UK

Exelixis (EXEL) Reports Break-Even Earnings for Q1 - Yahoo Lifestyle UK

Exelixis (EXEL) Reports Break-Even Earnings for Q1 - Yahoo Lifestyle UK

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May - Business Wire

GAMMA Investing LLC Takes Position in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC - Yahoo Movies UK

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality - Simply Wall St

Exelixis (EXEL) International Revenue Performance Explored

Exelixis (EXEL) International Revenue Performance Explored - Yahoo Canada Finance

Exelixis (EXEL) Announces Results From Phase II HNSCC Study - Yahoo New Zealand News

Exelixis: With Patent Litigation Decision Due Soon. There Are Options (NASDAQ:EXEL) - Seeking Alpha

Exelixis, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance

The Analyst Verdict: Exelixis In The Eyes Of 5 Experts

Exelixis (EXEL) Shares Cross Below 200 DMA - Nasdaq

Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short

Earnings call: Exelixis maintains 2024 guidance on strong Q1 results - Investing.com

Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short - Yahoo Finance

Exelixis (EXEL) Q1 2024 Earnings Call Transcript

Ähnlich wie EXEL